Afabetoran Shows Promise in Lupus Clinical Trial
News related to:Beeline Medicines Corporation · 3 min read
STAMFORD, Conn., Oct. 27, 2026 /CourierPR/ -- Beeline Medicines Corporation, a clinical-stage biotechnology company focused on developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases, announced today that the Phase 2 trial data of afimetoran in systemic lupus erythematosus (SLE) will be presented as a late-breaking oral presentation at the American College of Rheumatology (ACR) Convergence 2026, taking place November 6-11, 2026, in Orlando, Florida.
The presentation will take place on Wednesday, November 11 at 9:00 AM EST. The Phase 2 study, a global, double-blind, randomized, dose-ranging, placebo-controlled trial evaluating the efficacy, safety, and tolerability of investigational afimetoran in 248 adults with active systemic lupus erythematosus (SLE), demonstrated significant improvements in disease activity and quality of life.
The results showed a greater than 30 percentage-point difference in SRI-4 response versus placebo at all three doses evaluated (p<0.001). Afimetoran also showed improvements across secondary endpoints, including overall disease activity, skin and joint manifestations, corticosteroid reduction, and physician- and patient-reported outcomes. In addition, the trial demonstrated rapid and consistent activity in pharmacodynamic markers relevant to lupus pathobiology, including type I interferon (IFN), C3/C4, and anti-dsDNA antibodies. Afimetoran was generally well tolerated, with no new safety signals observed.
The late-breaking oral presentation will feature data showing afimetoran met the trial's primary endpoint, with a greater than 30 percentage-point difference in SRI-4 response versus placebo at all three doses evaluated (p<0.001). Afimetoran also showed improvements across secondary endpoints, including overall disease activity, skin and joint manifestations, corticosteroid reduction, physician- and patient-reported outcomes. In addition, afimetoran demonstrated rapid and consistent activity in pharmacodynamic markers relevant to lupus pathobiology, including type I interferon (IFN), C3/C4, and anti-dsDNA antibodies. Afimetoran was generally well tolerated, with no new safety signals observed.
The results show afimetoran reduces systemic and cutaneous disease activity in SLE and support afimetoran's advancement into planned pivotal development in both SLE and cutaneous lupus erythematosus (CLE).
Two preclinical posters will also be presented, highlighting afimetoran's activity in animal models of lupus nephritis (LN) and rheumatoid arthritis (RA). These preclinical results further highlight afimetoran's mechanism of action and reinforce its ability to suppress key drivers of immune-mediated inflammation, potentially supporting its expansion into these indications for future clinical development.
The Phase 2 study (NCT04895696) is a global, double-blind, randomized, dose-ranging, placebo-controlled trial evaluating the efficacy, safety, and tolerability of investigational afimetoran in 248 adults with active systemic lupus erythematosus (SLE). The trial enrolled adults aged 18 to 70 years with active moderate-to-severe SLE despite ongoing background treatment. Participants were randomized 1:1:1:1 to receive once-daily oral afimetoran at 1 of 3 dose levels or placebo through Week 48, in addition to protocol-permitted background standard of care medications, including corticosteroids with a mandatory corticosteroid taper. The primary endpoint assessed SLE Responder Index-4 (SRI-4) response at Week 48. Secondary endpoints assessed measures of disease activity including low disease activity, skin and joint manifestations, corticosteroid reduction, physician global assessment, and quality of life.
Afimetoran is an investigational selective, oral, once-daily, equipotent small-molecule inhibitor of Toll-like receptors 7 and 8 (TLR7 and TLR8), targets that play complementary and critical roles in lupus pathogenesis. Human genetics directly implicate TLR7 as a disease driver in lupus, while the biology of TLR8 contributes to pro-inflammatory cytokine production and immune responses, leading to potential progressive disease activity and irreversible organ damage. By blocking these components of the immune cascade, afimetoran has been shown to rapidly and substantially suppress signaling pathways in innate immune cells and B cells implicated in the pathology of various autoimmune diseases, including systemic and cutaneous lupus erythematosus.
The Phase 2 study enrolled 248 adults with active systemic lupus erythematosus (SLE) and randomized them to receive once-daily oral afimetoran at 1 of 3 dose levels or placebo. Participants were enrolled between the ages of 18 and 70, and all had active moderate-to-severe SLE despite ongoing background treatment. The primary endpoint was the SRI-4 response at Week 48, and secondary endpoints included measures of disease activity, skin and joint manifestations, corticosteroid reduction, physician and patient-reported outcomes, and pharmacodynamic markers such as type I interferon (IFN), C3/C4, and anti-dsDNA antibodies. Afimetoran was generally well tolerated, with no new safety signals observed.
The late-breaking oral presentation will feature data showing afimetoran met the trial's primary endpoint, with a greater than 30 percentage-point difference in SRI-4 response versus placebo at all three doses evaluated (p<0.001). Afimetoran also showed improvements across secondary endpoints, including overall disease activity, skin and joint manifestations, corticosteroid reduction, physician- and patient-reported outcomes.